Secondary analysis of the PanaMa trial (189 of 248 patients with RAS wild-type mCRC): high CT-derived muscle/bone ratio was linked to longer PFS (HR 0.43) and OS (HR 0.41) with FU/FA plus panitumumab, not FU/FA alone; panitumumab improved PFS only with high MBR.
Secondary analysisn = 189
Keyl et al. Deep Learning-Derived Sarcopenia Marker Predicts Benefit from Anti-EGFR Therapy in Patients with RAS Wild-type Metastatic Colorectal Cancer